公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study | Park K.; Jӓnne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU ; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. | Cancer | 14 | 10 | |
2020 | Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies | Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG ; Mitsudomi T.; Lee J.S. | Cancer Research and Treatment | 5 | 5 | |
2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 452 | 443 | |
2021 | Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium | Shimizu T.; Kim D.-W.; Loong H.H.; CHIA-CHI LIN ; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W. | Asia-Pacific Journal of Clinical Oncology | 2 | 1 | |
2020 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study | Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG ; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. | The Lancet Respiratory Medicine | 39 | 37 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 |